Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135Phase 2Recruiting
- Sponsor
- SCRI Development Innovations
- Start
- Oct 2023
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab, talquetamab in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Oct 2023; status: recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05972135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972135.